[Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005568
German
Original Title: Axicabtagen-Ciloleucel (DLBCL und HGBL, Zweitlinie) - Addendum zum Projekt A23-66
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a23-106.html
Year Published: 2023
URL for published report: https://www.iqwig.de/download/a23-106_axicabtagen-ciloleucel_addendum-zum-projekt-a23-66_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A23-106
MeSH Terms
  • Lymphoma, Large B-Cell, Diffuse
  • Biological Products
  • Immunotherapy, Adoptive
  • Antineoplastic Agents, Immunological
  • Receptors, Chimeric Antigen
Keywords
  • Axicabtagene Ciloleucel
  • Lymphoma – Large B-Cell – Diffuse
  • Benefit Assessment
  • NCT03391466
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.